ReviewTherapeutic advances in infectious disease
Polio: Background and perspective on how international travel can be made safe against polio.
Review in Therapeutic advances in infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Waning immunity drives respiratory virus evolution and reinfection.Evolution, medicine, and public health · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
International spread of polio continues to be a Public Health Emergency of International Concern since its declaration by the World Health Organization in 2014 and its reiteration in 2024. In 2023 and 2024, two countries remained endemic for wild poliovirus (WPV) but 20 countries reported polio outbreaks due to vaccine-derived polioviruses (VDPVs) in 2023 and 10 countries in 2024 (up to mid-June). Guidelines from various agencies recommend polio vaccination before travelling to or from polio-affected countries, or attending mass gatherings anywhere in the world, particularly if the crowd is international. Immunity protects against polio paralysis but not against poliovirus re-infection, irrespective of which vaccine was involved - live attenuated oral polio vaccine (OPV) or inactivated poliovirus vaccine (IPV). Infection with WPV or circulating VDPV in the vast majority of non-immune individuals (first infection) is asymptomatic, while they are efficient virus transmitters. Re-infections in immune individuals are always asymptomatic, but they are also infectious and may act as source for further transmission, although less efficiently than the former. Thus, travellers can become transmission vectors, illustrated by many episodes of importations of WPV or VDPVs into polio-free countries in recent years. The route of poliovirus transmission remains controversial, with many believing it to be faecal-oral, but epidemiological analysis is consistent with respiratory route and not faecal-oral. Transmission occurs person-to-person during social contact. Travellers must ensure they are adequately immunised to avoid polio, and becoming vectors of virus importation. The vaccine efficacy (VE) of OPV is highly variable - high in temperate climate countries, particularly rich countries, but low or very low in tropical low-income countries. On the other hand, VE of IPV is excellent everywhere irrespective of geography.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.